


EFV + ABC-3TC versus EFV + TDF-FTC **ASSERT Trial**



Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC ASSERT: Study Design

- Background: Randomized, open label, phase 3 study comparing tenofovir DF-emtricitabine plus efavirenz with zidovudine-lamivudine plus efavirenz in antiretroviral-naïve adults with HIV
- Inclusion Criteria (n = 385)
 - Antiretroviral-naïve adults
 - Age ≥18 years
 - HIV RNA ≥1,000 copies/mL
 - HLA-B*5701 negative
 - CrCl ≥50 mL/min
 - No AIDS-defining condition or HBV infection
- Treatment Arms
 - Efavirenz + abacavir-lamivudine
 - Efavirenz + tenofovir DF-emtricitabine


Source: Post FA, et al. J Acquir Immune Defic Syndr. 2010;55:49-57.





Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC ASSERT: Results

Week 48 Virologic Response (Intent-to-Treat Analysis)




Source: Post FA, et al. J Acquir Immune Defic Syndr. 2010;55:49-57.



Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC ASSERT: Renal Biomarkers

Week 48: Changes in Markers of Renal Tubular Function from Baseline





Efavirenz + ABC-3TC vs. Efavirenz + TDF-FTC ASSERT: Conclusions


Interpretation: "The study showed no difference in estimated glomerular filtration rate between the arms, however, increases in markers of tubular dysfunction were observed in the tenofovir/emtricitabine arm, the long-term consequence of which is unclear. A significant difference in efficacy favoring tenofovir/emtricitabine was observed."

Source: Post FA, et al. J Acquir Immune Defic Syndr. 2010;55:49-57.



Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC ASSERT: Bone Effects


Week 48: Changes in Spine and Hip Bone Mineral Density from Baseline





Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC ASSERT: Bone Effects

Week 48: Proportion of Subjects with Decrease in BMD from Baseline



Bone Density Loss



Acknowledgments

The National HIV Curriculum is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.





